Alzheimer’s News TodayDaily Alzheimer’s Pill Slows Brain Shrinkage, Boosts Cognition

⚠️ Small Study / Early Comparative Evidence

A 508-patient Phase 2b/3 trial of once-daily oral blarcamesine in mild cognitive impairment due to Alzheimer’s reported reduced brain atrophy and cognitive decline at 48 weeks. Extension analyses presented at AD/PD 2026 suggest sustained benefit through nearly 3 years, with long-term comparisons drawn against a matched ADNI external control.

Clinical Considerations

• Reductions in brain atrophy were reported across whole brain (37.7%), total grey matter (63.5%), and temporal lobe (69.2%) after 48 weeks of treatment.
• Cognitive (ADAS-Cog13), functional (ADCS-ADL), and disease severity (CDR-SB) measures all showed associations with structural preservation, though analyses are sponsor-presented and not yet peer-reviewed in this update.
• Sponsor reported 77-week delay in disease progression versus a matched ADNI external control — a non-randomized comparison that does not establish causality.
• A genetically defined subgroup (ABCLEAR3) showed a roughly 78% stronger volume-cognition association than the overall population; the subgroup pre-specification and validation status warrant scrutiny.
• Most common drug-related side effect was dizziness, generally mild to moderate and transient.

Practice Applications

• Interpret the extension data as hypothesis-generating; external ADNI controls do not substitute for randomized long-term comparison.
• Recognize that genetically defined subgroup signals require independent replication before clinical weighting.
• Avoid positioning blarcamesine as a disease-modifying option outside the trial context; regulatory status remains investigational.
• Monitor for peer-reviewed publication and any forthcoming regulatory submissions tied to the AD/PD 2026 dataset.